Assembly Biosciences
ASMB · Nasdaq · United States
Share price · ASMB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ASMB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+5.7%
- Day beforeEarnings date (period ending 2026-09-30)
- 12 Nov 2026-9.8%
- 13 Oct 2026-10.7%
Nothing announced by ASMB that day or the session before.
- 15 Sep 2026-9.8%
Nothing announced by ASMB that day or the session before.
- 17 Aug 2026-8.9%
- 14 Aug 2026+10.0%
- 13 Aug 2026+10.7%
- 26 Jun 2026+10.2%
Nothing announced by ASMB that day or the session before.
- 25 Jun 2026-5.3%
Nothing announced by ASMB that day or the session before.
- 24 Jun 2026-4.4%
Nothing announced by ASMB that day or the session before.
Share of unusual movement by asset
For each asset, the share of ASMB's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 21% |
| Sessions with no dated event | — | 79% |
No dated announcements about its assets since 3 Sep 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | HSV helicase-primase complexSmall molecule | Herpes Simplex Virus Infection Genital Herpes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.0M | $20M | $29M+ $285M short-term inv. | $20M-$17M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $13M | $15M | $32M+ $288M short-term inv. | $3.9M-$15M operating cash flow | report ↗ |
| 2026-Q1 | $8.2M | $15M | $31M+ $195M short-term inv. | $9.1M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $11M | $17M | $23M+ $210M short-term inv. | $9.2M-$15M operating cash flow | report ↗ |
| 2025-Q2 | $9.6M | $16M | $24M+ $51M short-term inv. | $10M-$17M operating cash flow | report ↗ |
| 2025-Q1 | $9.4M | $15M | $23M+ $68M short-term inv. | $8.8M-$23M operating cash flow | report ↗ |
| 2024-Q3 | $6.8M | $14M | $28M+ $67M short-term inv. | $9.6M-$15M operating cash flow | report ↗ |
| 2024-Q2 | $8.5M | $16M | $19M+ $90M short-term inv. | $11M-$17M operating cash flow | report ↗ |
| 2024-Q1 | $5.8M | $12M | $19M+ $94M short-term inv. | $9.1M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $11M | $27M+ $20M short-term inv. | $14M-$14M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $13M | $22M+ $38M short-term inv. | $17M-$14M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $15M | $43M+ $30M short-term inv. | $19M-$23M operating cash flow | report ↗ |
| 2022-Q3 | — | $18M | $55M+ $54M short-term inv. | $23M-$20M operating cash flow | report ↗ |
| 2022-Q2 | — | $18M | $43M+ $74M short-term inv. | $24M-$18M operating cash flow | report ↗ |
| 2022-Q1 | — | $17M | $51M+ $72M short-term inv. | $23M-$28M operating cash flow | report ↗ |
| 2021-Q3 | $6.3M | $18M | $71M+ $110M short-term inv. | $19M-$19M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $65M | $58M+ $190M short-term inv. | $1.5M-$41M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $29M | $56M | $38M+ $74M short-term inv. | $10M-$51M operating cash flow | report ↗ |
| 2023-FY | $7.2M | $49M | $20M+ $110M short-term inv. | $15M$23M operating cash flow | report ↗ |
| 2022-FY | $0 | $70M | $52M+ $39M short-term inv. | $23M-$84M operating cash flow | report ↗ |
| 2021-FY | $6.3M | $69M | $46M+ $101M short-term inv. | $32M-$93M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($252K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Okazaki Jason A · director, CEO and President | Open-market sale | 6,133 | $19.61 | $120K | Form 4 |
| 2026-11-02 | Gaggar Anuj · Chief Medical Officer | Open-market sale | 2,564 | $19.61 | $50K | Form 4 |
| 2026-11-02 | White Nicole S · Chief Manufacturing Officer | Open-market sale | 2,564 | $19.61 | $50K | Form 4 |
| 2026-11-02 | Bjorkquist Jeanette M · PFO and PAO | Open-market sale | 718 | $19.61 | $14K | Form 4 |
| 2026-11-02 | Okazaki Jason A · director, CEO and President | Open-market sale | 69 | $20.35 | $1K | Form 4 |
| 2026-11-02 | Gaggar Anuj · Chief Medical Officer | Open-market sale | 29 | $20.35 | $590 | Form 4 |
| 2026-11-02 | White Nicole S · Chief Manufacturing Officer | Open-market sale | 29 | $20.35 | $590 | Form 4 |
| 2026-11-02 | Bjorkquist Jeanette M · PFO and PAO | Open-market sale | 9 | $20.35 | $183 | Form 4 |